{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:38:06Z","timestamp":1758123486286,"version":"3.41.2"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has posed a constant threat to human beings and the world economy for more than two years. Vaccination is the first choice to control and prevent the pandemic. However, an effective SARS-CoV-2 vaccine against the virus infection is still needed. This study designed and prepared four kinds of virus-like particles (VLPs) using an insect expression system. Two constructs encoded wild-type SARS-CoV-2 spike (S) fused with or without H5N1 matrix 1 (M1) (S and SM). The other two constructs contained a codon-optimized spike gene and\/or M1 gene (mS and mSM) based on protein expression, stability, and ADE avoidance. The results showed that the VLP-based vaccine could induce high SARS-CoV-2 specific antibodies in mice, including specific IgG, IgG1, and IgG2a. Moreover, the mSM group has the most robust ability to stimulate humoral immunity and cellular immunity than the other VLPs, suggesting the mSM is the best immunogen. Further studies showed that the mSM combined with Al\/CpG adjuvant could stimulate animals to produce sustained high-level antibodies and establish an effective protective barrier to protect mice from challenges with mouse-adapted strain. The vaccine based on mSM and Al\/CpG adjuvant is a promising candidate vaccine to prevent the COVID-19 pandemic.<\/jats:p>","DOI":"10.3389\/fcimb.2022.967493","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T05:49:36Z","timestamp":1658123376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins"],"prefix":"10.3389","volume":"12","author":[{"given":"Jing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lichao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wancheng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linzhu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2021.1925267","article-title":"Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population","author":"Biswas","year":"2021","journal-title":"Int. Rev. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/vaccines10020250","article-title":"Optimization, production, purification and characterization of HIV-1 gag-based virus-like particles functionalized with SARS-CoV-2","volume":"10","author":"Boix-Besora","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001501","article-title":"Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle","volume":"3","author":"Bright","year":"2008","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1016\/j.vaccine.2007.01.106","article-title":"Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin","volume":"25","author":"Bright","year":"2007","journal-title":"Vaccine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/d41586-021-03619-8","article-title":"Beyond omicron: what's next for COVID's viral evolution","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/d41586-021-03672-3","article-title":"Omicron likely to weaken COVID vaccine protection","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/vaccines9080920","article-title":"Influenza virus-like particle (VLP) vaccines expressing the SARS-CoV-2 s glycoprotein, S1, or S2 domains","volume":"9","author":"Chu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/vaccines9080920","article-title":"Influenza virus-like particle (VLP) vaccines expressing the SARS-CoV-2 s glycoprotein, S1, or S2 domains","volume":"9","author":"Chu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.chom.2020.08.002","article-title":"Approaches and challenges in SARS-CoV-2 vaccine development","volume":"28","author":"Dagotto","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0189721","DOI":"10.1128\/jvi.01897-21","article-title":"The \"LLQY\" motif on SARS-CoV-2 spike protein affects s incorporation into virus particles","volume":"96","author":"Du","year":"2022","journal-title":"J. Virol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009453","article-title":"A human coronavirus evolves antigenically to escape antibody immunity","volume":"17","author":"Eguia","year":"2021","journal-title":"PLoS Pathog."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1016\/j.jaip.2021.07.016","article-title":"SARS-CoV-2 vaccines: Where are we now","volume":"9","author":"Flanagan","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009897","article-title":"Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection","volume":"17","author":"Geng","year":"2021","journal-title":"PLoS Pathog."},{"key":"B17","doi-asserted-by":"publisher","first-page":"100786","DOI":"10.1016\/j.nmni.2020.100786","article-title":"Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach","volume":"38","author":"Ghorbani","year":"2020","journal-title":"N. Microbes N. Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10529-021-03211-0","article-title":"Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2","volume":"44","author":"Hemmati","year":"2022","journal-title":"Biotechnol. Lett."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm3131","article-title":"Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission","volume":"6","author":"Horiuchi","year":"2021","journal-title":"Sci. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41541-021-00324-5","article-title":"Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models","volume":"6","author":"Kalnin","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12275-022-1608-z","article-title":"Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2","volume":"60","author":"Kim","year":"2022","journal-title":"J. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"15701","DOI":"10.1038\/s41598-018-34171-7","article-title":"Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis","volume":"8","author":"Kirchdoerfer","year":"2018","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1126\/science.acx9738","article-title":"Where did \u2018weird\u2019 omicron come from","volume":"374","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11427-013-4484-2","article-title":"Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus tian tan prime-boost immunization","volume":"56","author":"Liu","year":"2013","journal-title":"Sci. China Life Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1016\/j.vaccine.2011.06.111","article-title":"Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) s glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s10529-015-1856-7","article-title":"Enhanced production of porcine circovirus type 2 (PCV2) virus-like particles in Sf9 cells by translational enhancers","volume":"37","author":"Liu","year":"2015","journal-title":"Biotechnol. Lett."},{"key":"B28","doi-asserted-by":"publisher","first-page":"104971","DOI":"10.1016\/j.meegid.2021.104971","article-title":"Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic","volume":"93","author":"Li","year":"2021","journal-title":"Infect. Genet. Evol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/microorganisms9071479","article-title":"Possible targets of pan-coronavirus antiviral strategies for emerging or re-emerging coronaviruses","volume":"9","author":"Li","year":"2021","journal-title":"Microorganisms"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7826","DOI":"10.1016\/j.vaccine.2011.07.099","article-title":"Safety and immunogenicity of a virus-like particle pandemic influenza a (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico","volume":"29","author":"Lopez-Macias","year":"2011","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"107757","DOI":"10.1016\/j.bej.2020.107757","article-title":"Production of influenza virus-like particles using recombinant insect cells","volume":"163","author":"Matsuda","year":"2020","journal-title":"Biochem. Eng. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.abl8506","article-title":"Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants","volume":"374","author":"Mccallum","year":"2021","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/all.15080","article-title":"A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2","volume":"77","author":"Mohsen","year":"2022","journal-title":"Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1042\/BST20210859","article-title":"The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines","volume":"49","author":"Murano","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl6251","article-title":"Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain","volume":"375","author":"Nabel","year":"2022","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"w20249","DOI":"10.4414\/smw.2020.20249","article-title":"Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis","volume":"150","author":"Negro","year":"2020","journal-title":"Swiss Med. Wkly"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3390\/vaccines9121409","article-title":"VLP-based COVID-19 vaccines: An adaptable technology against the threat of new variants","volume":"9","author":"Prates-Syed","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"eabn4947","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of the omicron variant in south Africa","author":"Pulliam","year":"2022","journal-title":"Science 376:"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4161\/hv.4.1.5559","article-title":"Virus-like particles as a vaccine delivery system: myths and facts","volume":"4","author":"Roy","year":"2008","journal-title":"Hum. Vaccin"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1016\/j.vaccine.2010.06.044","article-title":"In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine","volume":"28","author":"Song","year":"2010","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-like particles: Revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2021","journal-title":"Front. Microbiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.ijbiomac.2020.05.239","article-title":"A recombinant lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2","volume":"160","author":"Wang","year":"2020","journal-title":"Int. J. Biol. Macromol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"9775","DOI":"10.3390\/ijms21249775","article-title":"The current status of drug repositioning and vaccine developments for the COVID-19 pandemic","volume":"21","author":"Won","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1260-1263.","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","author":"Wrapp","year":"2020","journal-title":"Science 367:"},{"key":"B49","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/vim.2021.0018","article-title":"Generation and evaluation of recombinant baculovirus coexpressing gp5 and m proteins of porcine reproductive and respiratory syndrome virus type 1","volume":"34","author":"Xu","year":"2021","journal-title":"Viral Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature02463","article-title":"A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice","volume":"428","author":"Yang","year":"2004","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.821664","article-title":"Characterization of two heterogeneous lethal mouse-adapted SARS-CoV-2 variants recapitulating representative aspects of human COVID-19","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Immunol."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm3302","article-title":"Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains","volume":"14","author":"Ying","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.967493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T05:49:40Z","timestamp":1658123380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.967493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":53,"alternative-id":["10.3389\/fcimb.2022.967493"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.967493","relation":{},"ISSN":["2235-2988"],"issn-type":[{"type":"electronic","value":"2235-2988"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"article-number":"967493"}}